1. Home
  2. NBXG vs GERN Comparison

NBXG vs GERN Comparison

Compare NBXG & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neuberger Berman Next Generation Connectivity Fund Inc.

NBXG

Neuberger Berman Next Generation Connectivity Fund Inc.

HOLD

Current Price

$16.70

Market Cap

1.0B

Sector

Finance

ML Signal

HOLD

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.26

Market Cap

808.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NBXG
GERN
Founded
N/A
1990
Country
United States
United States
Employees
N/A
258
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
808.3M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
NBXG
GERN
Price
$16.70
$1.26
Analyst Decision
Hold
Analyst Count
0
3
Target Price
N/A
$2.17
AVG Volume (30 Days)
218.1K
13.9M
Earning Date
01-01-0001
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$26.91
Revenue Next Year
N/A
$43.75
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.32
$1.04
52 Week High
$16.59
$2.01

Technical Indicators

Market Signals
Indicator
NBXG
GERN
Relative Strength Index (RSI) 75.07 34.40
Support Level $14.40 $1.22
Resistance Level N/A $1.29
Average True Range (ATR) 0.31 0.06
MACD 0.08 -0.00
Stochastic Oscillator 87.44 21.15

Price Performance

Historical Comparison
NBXG
GERN

About NBXG Neuberger Berman Next Generation Connectivity Fund Inc.

Neuberger Berman Next Generation Connectivity Fund Inc. is a non-diversified, closed-end management investment company. The fund's investment objectives are to provide capital appreciation and income. Under normal market conditions, the Fund will invest at least 80% of its total assets in equity securities issued by U.S. and non-U.S. companies, in any market capitalization range, that is relevant to the theme of investing in NextGen Companies.

About GERN Geron Corporation

Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.

Share on Social Networks: